Ribo Life Science Successfully Debuts on Hong Kong Main Board, Marking a Milestone in siRNA Therapy

Introduction

On January 10, 2026, Ribo Life Science Co., Ltd. officially commenced trading on the Hong Kong Stock Exchange Main Board under the stock code 06938.HK. This event stands as a pivotal moment for the company and represents a significant advancement for the entire siRNA therapeutics sector in China. The successful listing not only boosts Ribo's capital but also enhances the visibility of the siRNA industry, attracting global investor interest.

Overview of the Offering

Ribo Life Science released a total of 31,610,400 shares at an offering price of HKD 57.97 per share, securing over HKD 1.8 billion in gross proceeds. The initial public offering (IPO) saw overwhelming demand, being oversubscribed over 100 times domestically and 16.7 times in overseas placements. This reflects a strong investor confidence in the siRNA sector and Ribo’s capabilities in this rapidly evolving market.

Company Background

Founded with a vision to innovate in biopharmaceuticals, Ribo specializes in small interfering RNA (siRNA) therapeutics. The company has developed several cutting-edge therapeutic solutions targeting diseases such as cardiovascular, metabolic, liver, and kidney disorders. With a fully integrated research and development platform, Ribo is poised to advance its core operations and clinical pipeline significantly.

Leadership Vision

Dr. Zicai Liang, the founder and CEO of Ribo Life Science, expressed gratitude toward global investors for their unwavering support. He emphasized that this listing marks a crucial milestone in Ribo's journey, allowing the company to leverage international capital markets to expedite the clinical development and commercialization of siRNA therapeutics. He assured stakeholders that the company aims to deliver groundbreaking treatments while creating sustainable value for shareholders.

Utilization of Proceeds

The funds raised through the IPO will be allocated across four key areas:
1. Advancing global multicenter clinical trials for core products;
2. Supporting the preclinical and clinical development pipeline;
3. Refining and enhancing siRNA delivery and other technological platforms;
4. Replenishing working capital and designating funds for routine corporate purposes.

R&D and Future Prospects

Ribo boasts research and development centers located in Suzhou, Beijing, and Gothenburg, Sweden, enabling a global network that supports the drug development process from discovery to clinical trials. Their innovative RiboGalSTARTM technology specifically targets the liver, facilitating the progression of multiple products into phase II clinical trials. The listing was sponsored by industry leaders China International Capital Corporation and Citigroup, which provided professional support for Ribo's entrance into the public markets.

Conclusion

As Ribo Life Science takes this bold step on the Hong Kong Stock Exchange, it symbolizes more than just a successful IPO; it represents the burgeoning potential of the siRNA therapeutics segment. With robust financial backing and a commitment to innovation, Ribo is well-positioned to spearhead advancements in biopharmaceuticals, aiming to provide revolutionary treatment solutions that pave the way for a healthier future. Investors and patients alike will be watching closely as Ribo embarks on this exciting journey.